Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy

Prostate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuc...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-09, Vol.15 (18), p.4537
Main Authors: Abusalem, Mohammed, Martiniova, Lucia, Soebianto, Sarita, DePalatis, Louis, Ravizzini, Gregory
Format: Article
Language:English
Subjects:
Androgens
Antigens
Biomarkers
Cancer
Cancer therapies
Care and treatment
Diagnosis
Enzymes
FDA approval
Health aspects
Ligands
Medical research
Membrane proteins
Molecular weight
Monoclonal antibodies
PET imaging
Photons
Positron emission tomography
Prostate cancer
Radiation therapy
Radioactivity
Radioisotopes
Radiotherapy
Review
Scintigraphy
Side effects
Therapeutic applications
Vitamin B
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuclide-based tracers for imaging and radiopharmaceuticals for PSMA targeted therapy. These compounds range from small molecule ligands to monoclonal antibodies (mAbs). Monoclonal antibodies play a crucial role in targeting cancer cell-specific antigens with a high degree of specificity while minimizing side effects to normal cells. The same mAb can often be labeled in different ways, such as with radionuclides suitable for imaging with Positron Emission Tomography (β+ positrons), Gamma Camera Scintigraphy (γ photons), or radiotherapy (β- electrons, α-emitters, or Auger electrons). Accordingly, the use of radionuclide-based PSMA-targeting compounds in molecular imaging and therapeutic applications has significantly grown in recent years. In this article, we will highlight the latest developments and prospects of radiolabeled mAbs that target PSMA for the detection and treatment of prostate cancer.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15184537